PRECLINICAL STUDY OF SUBCHRONIC TOXICITY OF THE DRUG ON THE BASIS OF ACADESINE IN RATS

Introduction At the national medical research center of оncology N.N. Blokhin preclinical toxicological studies of a lyophilized dosage form of a drug based on acadesin, a new antitumor drug, were conducted.
The aim of the study to study the subchronic toxicity of the drug on the basis of acadesine in rats to evaluate its toxicity.
Materials and methods The study was conducted on 40 noninbred male mongrel rats. The drug was administered intraperitoneal daily 15-fold in total doses of 750, 1150 and 2300 mg/kg. Clinical and laboratory tests were performed during the entire observation period (30 days). The pathomorphological study was performed on the 1st and 30 th day of observation.
Results It was found that the drug based on acadesin, when applied repeatedly to rats in all the studied doses, did not cause changes in the indicators of peripheral blood of animals, morphological changes in all the studied organs and tissues of animals (except the kidneys), functional changes in the state of the liver, heart, kidneys and gastrointestinal tract. However, morphologically revealed changes in the kidneys when using the drug in the total dose of 1150 mg/kg on the 1st and 30 th day of observation, and in the total dose of 2300 mg/kg only on the 30 th day of observation.
Conclusion The detected toxic effect of the drug based on acadesin on the kidneys of rats is dose-dependent. When using the drug in the course of the course at a total dose of 750 mg/kg, which is 60 times higher than the single therapeutic dose for rats (12.5 mg/kg), toxic manifestations were completely absent during the entire period of observation. This allowed us to recommend a drug based on acadesin for further research.

1. Лобанов К.В., Эрраис Лопес Л., Королькова Н.В. и др. Реконструкция пуринового метаболизма у Bacillus subtilis с целью получения штамма-продуцента AICAR – нового препарата широкого терапевтического применения. Acta Naturae 2011;2(9):83–93. [Lobanov K.V., Arrais Lopez L., Korolkova N.V. et al. Reconstruction of purine metabolism in Bacillus subtilis with the aim of obtaining strain-producer of AICAR – a new drug of a wide therapeutic use. Acta Naturae 2011;2(9):83–93. (In Russ.)].

2. Северин Е.С., Алейникова Т.Л., Осипов Е.В., Силаева С.А. Биологическая химия. М.: Медицинское информационное агентство, 2008. С. 253–8. [Severin E.S., Aleynikova T.L., Osipov E.V., Silaeva S.A. Biological Chemistry. Moscow: Medical News Agency, 2008. Pp. 253–8. (In Russ.)].

3. Глазунова В.А., Лобанов К.В., Шакулов Р.С. и др. Акадезин вызывает неапоптотическую гибель опухолевых клеток. Acta Naturae 2013;5(3):78–82. DOI: 10.32607/20758251-2013-5-3-74-78. [Glazunova V.A., Lobanov K.V., Shаkulov R.S. et al. Acadesine triggers non-apoptotic death in tumor cells. Acta Naturae 2013;5(3):78–82. (In Russ.)].

4. Swinnen J.V., Beckers A., Brusselmans K. et al. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 2005;65(6):2441–8. DOI: 10.1158/0008-5472.CAN-04-3025.

5. Sengupta T.K., Leclerc G.M., HsiehKinzer T.T. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-(β-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 2007;6(46):1–12. DOI: 10.1186/1476-4598-6-46.

6. Campàs C.C., Lopez J.M., Santidrián A.F. et al. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T-lymphocytes. Blood 2003;101:3674–80. DOI: 10.1182/blood-2002-07-2339.

7. Gaidhu M.P., Fediuc S., Anthony N.M. et al. Prolonged AICAR-induced AMP-kinase activation promotes energy dissipation in white adipocytes: novel mechanisms integrating HSL and ATGL. J Lipid Res 2009;50:704–15. DOI: 10.1194/jlr.M800480-JLR200.

8. Rutter G.A., da Silva Xavier G., Leclerc I. Rolesof 5’-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J 2003;375(Pt. 1):1–16. DOI: 10.1042/BJ20030048.

9. Pold R., Jensen L.S., Jessen N. et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 2005;54(4):928–34. DOI: 10.2337/diabetes.54.4.928.

10. Глазунова В.А., Миронов А.С., Шакулов Р.С. и др. АИКАР – противоопухолевый препарат широкого спектра действия. Тезисы. Онкологический журнал общественного объединения «Белорусское онкологическое общество» 2012;6:16. [Glazunova V.A., Mironov A.S., Shakulov R.S. et al. AIKAR – antitumor drug of a wide spectrum of action. Abstracts. Onkologicheskiy zhurnal obshchestvennogo ob’yedineniya “Belorusskoye onkologicheskoye obshchestvo” = Cancer Journal of the Public Association “Belarusian cancer society” 2012;6:16. (In Russ.)].

11. Van Den Neste E., Cazin B., Janssens A. et al. Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/ II study. Cancer Chemother Pharmacol 2013;71(3):581–91. DOI: 10.1007/s00280-012-2033-5.

12. Ланцова А.В., Санарова Е.В., Оборотова Н.А. и др. Разработка технологии получения инъекционной лекарственной формы на основе отечественной субстанции из пуринового нуклеозида АКВ-12. Российский биотерапевтический журнал 2014;13(3):33–9. [Lantsova A.V., Sanarova E.V., Oborotova N.A. et al. Development of technology for injectable dosage form based on the national substance of purine nucleoside AKV-12. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2014;13(3):33–9. (In Russ.)].

13. Игнатьева Е.В., Дмитричева Н.А., Ярцева И.В. Количественное определение пуринового нуклеозида АКВ-12 в моделях лекарственной формы. Российский биотерапевтический журнал 2013;12(2):36. [Ignat’yeva E.V., Dmitrieva N.A., Yartseva I.V. et al. Quantification of purine nucleoside AKV-12 in models of dosage forms. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2013;12(2):36. (In Russ.)].

14. Лобанов К.В., Шакуров Р.С., Глазунова В.А. и др. Биосинтетический акадезин – основа для создания перспективного противоопухолевого препарата. Российский биотерапевтический журнал 2012;11(2):33. [Lobanov K.V., Shakurov R.S., Glazunova V.A. et al. Biosynthetic acadesine the basis for the creation of a promising anticancer drug. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2012;11(2):33. (In Russ.)].

15. Лобанов К.В., Шакуров Р.С., Яроцкий С.В. и др. Доклиническое изучение биосинтетического акадезина. Российский биотерапевтический журнал 2013;12(2):54–4. [Lobanov K.V., Shakurov R.S., Yarotsky S.V. et al. Preclinical study of biosynthetic acadesine. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2013;12(2):54–4. (In Russ.)].

16. Гуськова Т.А. Токсикология лекарственных средств. 2-е изд., доп. М.: МВД, 2008. 196 с. [Gus’kova T.A. Toxicology of medicinal products. Ed. 2nd, add. M.: MVD, 2008. 196 p. (In Russ.)].

17. Ермакова Н.П., Меркулова И.Б., Коняева О.И. и др. Влияние препарата ЛХС-1208 на сердечно сосудистую систему. Российский биотерапевтический журнал 2018;17(3):70–80. [Ermakova N.P., Merkulova I.B., Konyaeva O.I. et al. Influence of the drug LHS-1208 on the cardiovascular system Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2018;17(3):70–80. (In Russ.)].

18. Волкова О.В., Елецкий Ю.К. Основы гистологии с гистологической техникой. Изд. 2-е, перераб. и доп. М.: Медицина, 1982. [Volkova O.V., Eletsky Yu.K. Fundamental so fhistology with histological technique. Ed. 2nd, revision and add. Moscow: Medicine, 1982. (In Russ.)].